RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.
BACKGROUND Eprosartan is a new nonphenyl angiotensin II receptor blocker , which has been approved for the treatment of hypertension . Although the drug has a relatively short plasma half-life of 5 to 9 h , clinical studies have suggested that its antihypertensive effect persists for 24 h. METHODS We assessed both the changes in 24-h and trough blood pressure ( BP ) ( last 4 h of the ambulatory BP while the patient was awake ) of eprosartan at doses of 600 and 1,200 mg once daily in a r and omized , double-blind , placebo-controlled trial . Ambulatory BP was monitored at placebo baseline and after 8 weeks of double-blind therapy . RESULTS Two hundred patients r and omized in the study with 177 patients completing the trial . The 24-h change in BP from baseline was 0.2/0.1 + /- 1.4/1.0 mm Hg , -7.9/ -5.4 + /- 1.0 mm Hg ( P < .0001 ) , and -7.4/-5.0 + /- 0.9 mm Hg ( P < .0001 ) in the placebo , 600-mg eprosartan , and 1,200-mg eprosartan groups , respectively . Changes in trough ambulatory BP showed significant reductions of -6.3/-4.1 + /- 1.6/1.1 mm Hg and -7.7/-5.5 + /- 1.5/1.0 mm Hg for 600 mg of eprosartan and 1,200 mg of eprosartan , respectively . CONCLUSIONS These data demonstrate that eprosartan at doses of 600 or 1200 mg significantly reduced BP throughout an entire 24-h dosing period . There were no differences between the 600- and 1,200-mg dose ; thus , 600 mg once daily should be the only dose used in the treatment of hypertension with eprosartan
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .